Objective: In this study, we investigated the efficacy and safety of remdesivir and tocilizumab
combination therapy against dexamethasone for the management of severe COVID-19 …

Objectives To assess the benefits of remdesivir in hospitalized COVID-19 patients receiving
combined immunomodulatory therapy (CIT) with dexamethasone and tocilizumab. Methods …

Abstract Background Coronavirus disease-2019 (COVID-19) remains a global public health
concern, and remdesivir plus dexamethasone combination therapy is suggested for patients …

The infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
generated many challenges to find an effective drug combination for hospitalized patients …

Aims To perform network meta‐analysis for a head‐to‐head comparison of various
interventions used in coronavirus disease 2019 (COVID‐19) on mortality, clinical recovery …

Rationale Remdesivir and dexamethasone reduced the severity of COVID-19 in clinical
trials. However, their individual or combined effectiveness in clinical practice remains …

Background There are limited data on outcomes of moderate to severe coronavirus disease
2019 (COVID-19) among patients treated with remdesivir and dexamethasone in a real …

Introduction Remdesivir and Dexamethasone represent the cornerstone of therapy for
critically ill patients with acute hypoxemic respiratory failure caused by Coronavirus Disease …

Background Remdesivir is an antiviral used to treat coronavirus disease 2019 (COVID-19),
which improves some clinical outcomes. Dexamethasone has been shown to be effective in …

Purpose Trials of tocilizumab in patients with severe COVID-19 pneumonia have
demonstrated mixed results, and the role of tocilizumab in combination with other treatments …